News summary

TRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease

Source: M Ventures • Published: 16 Nov 2026, 00:00

Summarized by Masters of Longevity from M Ventures.

TRIMTECH and Biogen announced a collaboration to develop CNS-active protein degraders.

TRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease
Key Takeaways
  • TRIMTECH and Biogen will collaborate to develop degraders.
  • TRIMTECH's TRIM21 degraders are reported to reach the CNS.
  • The agreement may provide up to $411 million plus royalties.
Read the full article at M Ventures ↗

Continue exploring

Recommended MoL Picks

MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.MoL PickMOTS-c: Where the Evidence EndsStudies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?